There have been few opportunities for value investors to purchase CSL shares, with the stock trading primarily above value in recent years

There have been few opportunities for value investors to purchase CSL shares, with the stock trading primarily above value in recent years. CSL is returning to value and has a positive outlook underpinned by an ageing population, increasing health care expenditure in emerging markets and greater recognition of the benefits of its therapies. The successful commercialisation of its research and development pipeline would provide further upside to earnings. For the full article published in Eureka Report (VIEW LINK)